Stocks · News reference
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib)
The FDA has accepted Celcuity's supplemental New Drug Application (sNDA) for REVTORPYK™ (gedatolisib) to treat HR+/HER2-, PIK3CA-mutant locally advanced or metastatic breast cancer.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Block To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for Magnite, Airbnb and Choice Hotels; cut targets for Unusual Machines, DraftKings, PDD and TeraWulf. DKNG and PDD downgraded.
HC Wainwright & Co. Maintains Buy Rating on Celcuity, Lowers Price Target
HC Wainwright & Co. has reaffirmed its 'Buy' rating on Celcuity Inc. while adjusting the price target to $150 from $155.
HC Wainwright & Co. Maintains Buy on Celcuity, Lowers Price Target to $150
Guggenheim Maintains Buy on Celcuity, Lowers Price Target to $169
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Celcuity Inc. announced its financial results for the third quarter ended September 30, 2026, alongside updates on the commercial launch of REVTORPYK™ and ongoing clinical trial progress.